Derrell Porter Sells Shares of ABOS
Derrell Porter sold 12,800 shares of ABOS for $29,824 on June 16, 2026.
Key Points
- Derrell Porter sold 12,800 ABOS shares at $2.33 each, totaling $29,824, on June 16, 2026.
- ABOS shares traded at $2.33, with strong institutional interest from RA Capital Management and others.
- Analysts from BTIG and B of A Securities maintain 'buy' ratings with price targets up to $11.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, Derrell Porter sold 12,800 shares of ABOS at a price of $2.33 each, resulting in a total transaction value of $29,824. This sale was not part of a pre-planned trading program.
Other Institutional Activity in ABOS
RA Capital Management, L.P. significantly increased its stake in ABOS by adding 6,060,606 shares, bringing its total to 20,992,669 shares valued at approximately $49.5 million. Sands Capital Alternatives, LLC also boosted its holdings by 303,030 shares, ending with 3,720,105 shares worth about $8.8 million. Alyeska Investment Group, L.P. made a substantial addition of 1,515,151 shares, reaching a total of 2,454,754 shares valued at $5.8 million. Franklin Resources Inc and Knollwood Investment Advisory, LLC maintained their positions without any change.
Acumen Pharmaceuticals, Inc. Stock Down 20.2%
ABOS shares are trading at $2.33. The stock has seen active trading among institutional investors, with recent significant additions to holdings by major funds.
Insider Buying and Selling at Acumen Pharmaceuticals, Inc.
Derrell Porter has been active in trading ABOS shares, including a purchase of 13,040 shares at $1.07 on June 17, 2026, followed by a sale of the same number of shares at $2.33. Additionally, Porter sold 6,460 shares at $2.35 on June 15, 2026.
Analysts Set New Price Targets
On March 17, 2026, BTIG maintained its 'buy' rating for ABOS, setting a price target of $8. Earlier, on January 27, BTIG also maintained a 'buy' rating with a target of $7. B of A Securities has consistently maintained a 'buy' rating, with a target of $8 set on November 18, 2025. The consensus among analysts is a 'buy' recommendation, with an average target price reflecting optimism for the company's future performance.
About ABOS
ABOS operates in the biotechnology sector, focusing on innovative therapies. The company is committed to advancing its research and development efforts to bring new solutions to market. Headquartered in the U.S., ABOS aims to address unmet medical needs through its cutting-edge scientific approach.
Bottom Line
Derrell Porter's recent sale of ABOS shares highlights ongoing insider activity, with significant transactions occurring over a few days. Investors keep an eye on institutional movements and analyst ratings to gauge the stock's potential. Remember, insider transactions like these are reported after the fact and don't necessarily indicate current positions.
Get Acumen Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABOS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.